Properties (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
olaparib
|
| gptkbp:clinicalTrials |
Phase III
NCT01844986 NCT02000622 NCT02855944 NCT02953457 NCT02184195 |
| gptkbp:contraindication |
pregnancy
breastfeeding severe liver impairment hypersensitivity to olaparib |
| gptkbp:date |
December 19, 2014
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
strong CYP3A inducers
strong CYP3A inhibitors |
| https://www.w3.org/2000/01/rdf-schema#label |
Lynparza
|
| gptkbp:lastProduced |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedAs |
gptkb:Lynparza
gptkb:France gptkb:Germany gptkb:India gptkb:Japan gptkb:United_Kingdom |
| gptkbp:patentExpiration |
2027
|
| gptkbp:provides |
ASCO guidelines
NICE guidelines ESMO guidelines NCCN_guidelines |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
anemia
fatigue headache nausea abdominal pain vomiting diarrhea insomnia constipation loss of appetite |
| gptkbp:skills |
100 mg
150 mg |
| gptkbp:triggerType |
PARP inhibitor
|
| gptkbp:usedFor |
treatment of pancreatic cancer
treatment of breast cancer treatment of prostate cancer treatment of ovarian cancer |